Qiwei Gai, MD
Hematology & Oncology · Westminster, MDNPI 1780889139
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $17,442 of the $24,202 with a category attached, or 72.1%. It is spread thinly across 27 manufacturers, the largest accounting for just 22.9%. 2025 is the largest year on record at $9,038, 2.5 times the $3,549 reported in 2019.
Across 74 payments — averaging $327.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$6K
- Incyte Corporation$4K
- Exelixis Inc.$3K
- Beigene USA, Inc.$3K
- Dova Pharmaceuticals$3K
- E.r. Squibb & Sons, L.L.C.$3K
- plus $3K from 21 others
Across 11 payments — averaging $5911.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$38K
- Bristol Myers Squibb$25K
- E.r. Squibb & Sons, L.L.C.$2K
What the payments were for
- Consulting fees$17,44272%
- Speaking & faculty fees$3,05013%
- Travel & lodging$1,4226%
- Food & beverage$2,0969%
- Education$1931%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 4 | $5,552 |
| Incyte Corporation | 6 | $3,611 |
| Exelixis Inc. | 14 | $3,278 |
| Beigene USA, Inc. | 3 | $3,000 |
| Dova Pharmaceuticals | 2 | $2,990 |
| E.r. Squibb & Sons, L.L.C. | 9 | $2,867 |
| Bayer | 2 | $883 |
| Daiichi Sankyo Inc. | 4 | $615 |
| Eisai Inc. | 3 | $166 |
| Amgen | 1 | $150 |
| Johnson & Johnson | 3 | $140 |
| Beone Medicines USA, Inc. | 1 | $134 |
| Astellas Pharma US Inc | 1 | $118 |
| GSK | 4 | $114 |
| Puma Biotechnology, Inc. | 1 | $112 |
| Biocryst US Sales Co., LLC | 1 | $98 |
| Novartis | 3 | $89 |
| Genentech USA, Inc. | 2 | $54 |
| Sanofi | 1 | $45 |
| Regeneron Healthcare Solutions, Inc. | 2 | $35 |
| Agios Pharmaceuticals, Inc. | 1 | $34 |
| Merck | 1 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
| AbbVie | 1 | $16 |
| Novocure Inc. | 1 | $14 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,202 in reported general payments places this provider in the 85th percentile of 242 hematology & oncology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 71 | $943,889 |
| CabometyxCabozantinib S-Malate | 19 | $488,662 |
| JakafiRuxolitinib Phosphate | 25 | $429,360 |
| LumakrasSotorasib | 18 | $387,686 |
| ImbruvicaIbrutinib | 22 | $370,253 |
| KisqaliRibociclib Succinate | 14 | $213,102 |
| CalquenceAcalabrutinib Maleate | 14 | $185,567 |
| BrukinsaZanubrutinib | 13 | $177,183 |
| SprycelDasatinib | 12 | $112,604 |
| EliquisApixaban | 69 | $46,964 |
| XareltoRivaroxaban | 30 | $28,448 |
| Exemestane | 43 | $8,374 |
| Anastrozole | 310 | $6,979 |
| Tamoxifen Citrate | 73 | $2,447 |
| Hydroxyurea | 110 | $1,983 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Exelixis Inc.Cabometyx | $3,278 | $488,66219 claims |
| Incyte CorporationJakafi | $3,611 | $429,36025 claims |
| AmgenLumakras | $150 | $387,68618 claims |
| NovartisKisqali | $89 | $213,10214 claims |
| AstraZenecaCalquence | $5,552 | $185,56714 claims |
| Beigene USA, Inc.Brukinsa | $3,000 | $177,18313 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $2,867 | $112,60412 claims |
| Johnson & JohnsonXarelto | $140 | $28,44830 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 242 hematology & oncology providers in Maryland.
Other hematology & oncology in Westminster
- Ralph BocciaBethesda$3.1M
- Sandra SwainBethesda$1M
- Kashif AliSilver Spring$987K
- Ani BalmanoukianBaltimore$842K
- Benjamin LevyBaltimore$578K
- Patrick FordeBaltimore$269K
- Noah HahnBaltimore$133K
- Walid El AyassSalisbury$111K
- Arun BhandariAnnapolis$103K
- Huzefa BahrainBaltimore$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.